

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

1. Issuer's Identity		
CIK (Filer ID Number)	Previous Name(s) None	Entity Type
0001621221	REACTIVE MEDICAL INC.	© Corporation
Name of Issuer	KNIGHT KNOX	C Limited Partnership
ARTELO BIOSCIENCES, INC.	DEVELOPMENT CORP.	C Limited Liability Company
Jurisdiction of Incorporation/Organization		C General Partnership
NEVADA		C Business Trust
Year of Incorporation/Organization	n	COther
♥ Over Five Years Ago		
C Within Last Five Years (Specify Year)		
C Yet to Be Formed		



3. Related Persons				
3. Related Persons				
Last Name	First Name	Middle Name		
Gorgas	Gregory			
Street Address 1	Street Addr	ess 2		
c/o Artelo Biosciences, Inc.	888 Prosp	ect Street, Suite 210		
City	State/Province/Country	ZIP/Postal Code		
La Jolla	CALIFORNIA	92037		
Relationship: Execut	ive Officer Directo	r Promoter		
Clarification of Response (if Necessary	7)			
Last Name	First Name	Middle Name		
Matsui	Connie			
Street Address 1	Street Addr	ess 2		
c/o Artelo Biosciences, Inc. 888 Prospect Street, Suite 210				
City	State/Province/Country	ZIP/Postal Code		
La Jolla	CALIFORNIA	92037		
Relationship: Execut	ive Officer	r Promoter		

Last Name	F	irst Name			Middle	Name	
Emanuele		R.		Martin			
Street Address 1			Str	eet Address 2			
c/o Artelo Biosciences,	Inc.		88	88 Prospect Str	eet, Suite	210	
City	S	tate/Province/C	Country		ZIP/Pos	stal Code	
La Jolla		CALIFORNIA	\		92037		
Relationship:	Executive Executive	Officer	<u> </u>	Director		Promoter	
Clarification of Response	(if Necessary)						
Last Name		irst Name			Middle	Name	
Kelly		Steven					
Street Address 1				eet Address 2			
c/o Artelo Biosciences,	Inc.		88	88 Prospect Str	eet, Suite	210	
City	S	tate/Province/C	Country		ZIP/Pos	stal Code	
La Jolla		CALIFORNIA	\		92037		
							_
Relationship:	Executive	Officer		Director		Promoter	
Last Name		irst Name			Middle	Name	
Street Address 1			Str	eet Address 2			
c/o Artelo Biosciences,	Inc.		88	88 Prospect Str	eet, Suite	210	
City	S	tate/Province/C	Country ZIP/Postal Code		stal Code		
La Jolla		CALIFORNIA	\		92037		
Relationship:	Executive	Officer	V	Director		Promoter	
Clarification of Response	(if Necessary)						
Last Name		irst Name			Middle	Name	
Erbez		Georgia					
Street Address 1			Str	eet Address 2			
c/o Artelo Biosciences,	Inc.		88	88 Prospect Str	eet, Suite	210	
City	S	tate/Province/C	Country		ZIP/Pos	stal Code	
La Jolla		CALIFORNIA	\		92037		
	20.30	1				10.00	_
Relationship:	Executive	Officer		Director		Promoter	

4. Industry Group

C Agriculture	Health Care	Retailing
Banking & Financial Services	C Biotechnology	© Restaurants
C Commercial Banking	C Health Insurance	
C Insurance	C Hospitals & Physicians	Technology
C Investing	C Pharmaceuticals	C Computers
C Investment Banking	Other Health Care	C Telecommunications
C Pooled Investment Fund		C Other Technology
Other Banking & Financial O Services		Travel
	Manufacturing	C Airlines & Airports
© Business Services	Real Estate	C Lodging & Conventions
Energy C Coal Mining	C Commercial	C Tourism & Travel Services
C Electric Utilities	C Construction	C Other Travel
C Energy Conservation	C REITS & Finance	C Other
C Environmental Services	C Residential C Other Real Estate	
Oil & Gas	Other Real Estate	
C Other Energy		
5. Issuer Size		
Revenue Range	Aggregate Net Asset	t Value Range
C No Revenues	_	ite Net Asset Value
C \$1 - \$1,000,000	\$1 - \$5,000,0	000
\$1,000,001 - \$5,000,000	C \$5,000,001 -	- \$25,000,000
\$5,000,001 - \$25,000,000	\$25,000,001	- \$50,000,000
\$25,000,001 - \$100,000,000	C \$50,000,001	- \$100,000,000
C Over \$100,000,000	Over \$100,0	000,000
© Decline to Disclose	C Decline to D	Disclose
C Not Applicable	C Not Applica	able
C. Fodovol Evonontion(a)	and Evaluation(a) Claim	
6. Federal Exemption(s) apply)	and Exclusion(s) Clair	med (select all that
Rule 504(b)(1) (not (i), (ii)	Панта	
01 (111))	Rule 505	
Rule 504 (b)(1)(i)	Rule 506(b)	
Rule 504 (b)(1)(ii)	Rule 506(c)	
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)
	Investment Company Act Se	ection 3(c)
7. Type of Filing		
_	2019-01-08	
✓ New Notice Date of First Sale	2019-01-08	First Sale Yet to Occur
Amendment		
O Describer of Official		
8. Duration of Offering		7.2 00.00
Does the Issuer intend this offering to last	more than one year?	C Yes O No
O Type(a) of Consumition	Office of the state of the state of	annlu)
9. Type(s) of Securities (onered (select all that	apply)
Pooled Investment Fund Interests	Equity	
	Debt	

☐ Min	neral Property Securities	Option, Warrant or Other Right to Acquire Another Security
Exe Otl	curity to be Acquired Upon ercise of Option, Warrant or her Right to Acquire eurity	Other (describe)
10. E	Business Combina	tion Transaction
Is this of	ffering being made in connecti	on with a business combination C Vos No
	ion, such as a merger, acquisitation of Response (if Necessar	
11. N	Minimum Investme	nt
Minimu	m investment accepted from a	y outside \$ 25000 USD
40 0) - + :	
	Sales Compensati	Recipient CRD Number None
Recipie	III.	Recipient CRD Number
(Associa	ated) Broker or Dealer	None (Associated) Broker or Dealer CRD None
		Number
Street A	Address 1	Street Address 2
City		State/Province/Country ZIP/Postal Code
State(s)	of Solicitation	□ All States
13. 0	Offering and Sales	Amounts
Total Of	ffering Amount \$\begin{align*} \begin{align*} \begi	USD Indefinite
	mount Sold \$ 4192990	USD
Total Re	emaining to be \$ 5807010	USD ☐ Indefinite
	of Response (if Necessar: Offering Amount includes \$	
\$7,000		nts. Total Amount Sold includes
14. lı	nvestors	
	do not qualify as accredited	ring have been or may be sold to persons who nvestors, ted investors who already have invested in the
		ties in the offering have been or may be sold y as accredited investors, enter the total
	number of investors who all	eady have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Sales Commissions	\$ 0		USD	Estima	te
Finders' Fees	\$ 0		USD	☐ Estima	te
Clarification of Response (if Necessar	y)				
16. Use of Proceeds					
Provide the amount of the gross proce any of the persons required to be nam If the amount is unknown, provide an	ed as execut	ive officers, direct	ors or promote	rs in response	
	5	\$ 0		USD	Estimate
Clarification of Response (if Necessar	y)				
	— I				

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
 described and undertaking to furnish them, upon written request, the information furnished to
 offerees
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	ignature Name of Signer Title		Date
ARTELO BIOSCIENCES, INC.	/s/ Gregory Gorgas	Gregory Gorgas	President and Chief Executive Officer	2019-06-04